Introduction {#sec1}
============

The human genome contains 39 *HOX* genes divided among four clusters and classified into 13 paralogous groups based on sequence homology ([Figure 1](#fig1){ref-type="fig"}A). During embryonic stages of body axis elongation, newly formed tissues express *HOX* genes in sequential, contiguous domains consistent with their order in each cluster, i.e., colinearly. This phenomenon is evolutionarily conserved in bilaterian species and spatially assigns body segment-specific differentiation trajectories to axial progenitors of all three germ layers ([@bib24]). During formation of the posterior CNS, progenitors proximal to the node progressively transition from a 3′ to 5′ *HOX* expression profile as the primitive streak regresses ([@bib17]). This process produces nested and overlapping axial domains of *HOX* expression within the neuroepithelium of hindbrain rhombomeric (*HOX1-5*) and spinal cord cervical (*HOX5-9*), thoracic (*HOX9-10*), and lumbosacral (*HOX10-13*) vertebral segments ([Figure 1](#fig1){ref-type="fig"}A) ([@bib42]). The spatial variation of *HOX* expression along the rostrocaudal (R/C) axis of the posterior CNS diversifies the fates of neuroepithelial progeny and precisely restricts the development of specific neural subtypes to discrete axial positions ([@bib42]).

Retinoic acid (RA), wingless-type MMTV integration site protein family (Wnt), fibroblast growth factor (FGF), and growth differentiation factor (GDF) signaling intricately regulate *HOX* expression during posterior CNS development ([@bib31; @bib38]). Yet, it remains controversial how these factors should be applied to human pluripotent stem cells (hPSCs) to recapitulate full colinear *HOX* activation and enable deterministic patterning of diverse R/C *HOX* profiles, i.e., regional hindbrain or spinal cord phenotypes, during neural differentiation. RA is used ubiquitously to caudalize hPSC-derived neuroectoderm because its secretion by paraxial somitic mesoderm is believed to convert 3′ *HOX* genes in hindbrain and spinal cord neural tissues from an epigenetically repressed to a transcriptionally active state ([@bib15; @bib36; @bib3]). However, RA activates *HOX1-5* chromatin domains in a saltatory ([@bib36]) versus colinear manner, which patterns mouse (mPSC) and human PSC-derived neuroectoderm with a broad caudal hindbrain thru cervical spinal cord identity. This is evidenced by demonstrations that RA-mediated caudalization generates HOXB4^+^ ([@bib26]), HOXC4^+^/HOXA5^+^/HOXC6^−^/HOXC8^−^ ([@bib36]), HOXC5^+^/HOXC6^+^ ([@bib41; @bib53]), or HOXC6^+^/HOXC8^+^ ([@bib23; @bib25]) motor neurons (MNs), or HOXB4^+^ astrocytes ([@bib21]). Alternatively, Wnt and FGF treatments in the absence of RA can caudalize neurally differentiating mPSCs by inducing saltatory activation of *HOX1-9* paralogs to coarsely pattern a heterogeneous mixture of HOXC6^+^ cervical and HOXD9^+^ thoracic spinal tissues, which can be further caudalized to also contain HOXD10^+^ lumbar tissues upon GDF11 supplementation ([@bib36; @bib41]). Also, a recent report demonstrated that manipulation of Wnt and RA concentrations could yield MNs possessing hindbrain or rostral spinal phenotypes but more caudal and further partitioning of regional HOX identity was not achieved ([@bib35]). Overall, an approach for hPSC neural differentiation that recapitulates the precision, extent, and predictability of colinear *HOX* patterning observed in vivo remains elusive. Its development would enable unprecedented access to diverse regional phenotypes that populate posterior CNS tissues and generation of human disease models containing regional neural phenotypes with differential susceptibility to neurodegenerative disorders ([@bib6; @bib19; @bib43]).

Recent progress in understanding how the posterior CNS develops led us to consider other methods for in vitro *HOX* patterning. New evidence suggest that bipotent SOX2^+^/Brachyury(*T*)^+^ neuromesodermal progenitors (NMPs) residing in a stem zone proximal to the primitive streak's regressing node are the cell source for both the posterior neural tube and flanking paraxial mesoderm ([@bib12; @bib45; @bib51]). These NMPs are maintained by synergistic Wnt/β-catenin and FGF signaling from the node and primitive streak that induces SOX2 expression via activation of enhancer N1 ([@bib44; @bib45]). FGF signaling from the node also helps maintain the NMP state by repressing the expression of the neuroectoderm fate determinant PAX6 ([@bib5; @bib34]). As the node regresses, NMPs rostral to the stem zone experience a decline in FGF signaling, which initiates paraxial mesoderm differentiation (i.e., somite formation). Then, the somites secrete RA back to the presumptive neural tube, which induces PAX6 expression to generate definitive neuroectoderm of the posterior CNS ([@bib14; @bib37]). The discovery that Wnt/FGF signaling induces NMPs that progressively caudalize *HOX* expression and undergo RA-induced neuroectoderm differentiation to form the hindbrain and spinal cord suggests an alternative approach for patterning *HOX* expression in vitro. Guoti et al. recently had partial success recapitulating the *HOX*-expressing NMP state from hPSCs in vitro, but the NMP phenotype could only be maintained for 3 days preventing acquisition of more caudal HOX genes/proteins before exhibiting a mesodermal shift ([@bib16]). Also, they were unable to partition *HOX* patterning within hindbrain and spinal cord regions. Therefore, we proceeded to test whether (1) Wnt/β-catenin and FGF signaling could differentiate hPSCs to stable NMPs to permit full, colinear activation of *HOX* genes; (2) RA exposure could differentiate NMPs to neuroectoderm; (3) this approach to deriving human neuroectoderm could enable enhanced control of *HOX* patterning.

Using a chemically defined, monolayer neural differentiation system ([@bib29]), we determined that by temporally modulating Wnt/β-catenin and FGF signaling, hPSCs could be differentiated into pure SOX2^+^/Brachyury^+^ NMPs that were stable for 7 days. Over this period, the NMPs exhibited colinear activation of hindbrain, cervical, and thoracic *HOX* genes plus lumbosacral *HOX* genes with GDF11 supplementation. At any point during NMP propagation, a transition to RA was necessary and sufficient to induce PAX6^+^/SOX2^+^ neuroectodermal differentiation, precisely arrest progressive *HOX* activation, and thereby generate discrete HOX protein profiles indicative of distinct R/C domains. Overall, we demonstrate the ability to deterministically pattern neuroectoderm to diverse R/C domains by simply varying the amount of time NMPs spend under Wnt/β-catenin, FGF, and GDF signaling prior to RA exposure. Furthermore, we demonstrate that neuroectoderm of differing HOX expression profiles produce region-specific hindbrain, cervical, thoracic, and lumbar MN populations. Therefore, this temporal biphasic approach could be used to produce regional neural phenotypes from diverse hindbrain and spinal cord domains.

Results {#sec2}
=======

Regulation of *HOX* and *CDX* Expression by RA, Wnt/β-Catenin, and FGF Signaling {#sec2.1}
--------------------------------------------------------------------------------

We used the chemically defined "E6" method to investigate the effects of Wnt, FGF, RA, and GDF11 during hPSC neural differentiation because it lacks the use of small molecule inhibitors that could influence fate choices and does not form non-neural germ layers that could initiate unknown signaling crosstalk ([@bib29]). We first differentiated H9 human embryonic stem cells (hESCs) in E6 medium for 24 hr and then added RA, CHIR99021 (CHIR; a small molecule Wnt/β-catenin agonist), FGF8b, or their relevant combinations and monitored *HOX* expression by RT- and quantitative PCR (qPCR) over 4 days ([Figures 1](#fig1){ref-type="fig"}B--1D). The addition of RA or CHIR, but not FGF8b, induced temporal, progressive expression of *HOXA1*-*HOXC5* ([Figure 1](#fig1){ref-type="fig"}C). However, CHIR/FGF8b, but not RA/FGF8b, accelerated the progression of *HOX* activation inducing colinear activation of *HOXC6*, *HOXC8*, and *HOXC9* at levels ranging from 39- to 3,400-fold higher than the other treatments ([Figures 1](#fig1){ref-type="fig"}C and 1D). Moreover, the caudalizing effect of CHIR/FGF8b was not impeded by the addition of HX531, an RXR inhibitor, and CHIR but not RA treatment was able to reduce gene and protein expression of the midbrain/forebrain marker *OTX2* ([Figures 1](#fig1){ref-type="fig"}C--1E; [Figure S1](#app2){ref-type="sec"}). These results indicate that while RA can induce some degree of posterior identity indicated by *HOX1-5* expression, CHIR/FGF8b induces rapid patterning of differentiating hESCs to an OTX2^−^ posterior phenotype with caudal *HOX1-9* expression in an RA-independent manner. This is in agreement with other neural differentiation studies ([@bib16; @bib36])

Additionally, CHIR/FGF8b treatment yielded substantially elevated expression of *CDX* genes, which are the upstream regulators of *HOX* genes ([@bib38]): compared to RA, CHIR/FGF8b upregulated *CDX1* by \>6-fold, *CDX2* by \>1,800-fold, and *CDX4* by \>330-fold ([Figure 1](#fig1){ref-type="fig"}D). To confirm that CHIR-mediated *HOX* induction requires β-catenin signaling, we utilized the H9 ishcat2 line, which harbors a doxycycline-inducible β-catenin small hairpin RNA (shRNA) cassette ([@bib28]). Addition of doxycycline prior to CHIR treatment reduced β-catenin (*CTNNB1*) expression by 3-fold and decreased *HOXA1* and *HOXB1* expression by 14- and 15-fold, respectively ([Figure 1](#fig1){ref-type="fig"}F). In contrast, while doxycycline treatment also reduced β-catenin by 3-fold in RA-treated cells, it did not reduce *HOXA1* or *HOXB1* expression, suggesting RA-mediated induction of *HOX* transcription is β-catenin independent ([Figure 1](#fig1){ref-type="fig"}F). To verify sustained β-catenin signaling promotes progressive *HOX* activation, we induced *HOX* expression with CHIR/FGF8b for 1 day and continued the treatment for 3 days with and without doxycycline. Doxycycline treatment reduced *CTNNB1* by 4-fold, *HOXC8* by 2-fold, and *HOXC9* by 2-fold, indicating that sustained β-catenin signaling contributes to progressive *HOX* activation ([Figure 1](#fig1){ref-type="fig"}G).

Derivation of Stable NMPs Exhibiting Full Colinear *HOX* Activation {#sec2.2}
-------------------------------------------------------------------

Gouti et al. recently demonstrated that simultaneous induction of Wnt/β-catenin and FGF signaling can differentiate hPSCs to SOX2^+^/Brachyury(*T*)^+^ NMPs, but NMPs persisted for only 3 days before shifting to a mesodermal fate under their treatment regimen ([@bib16]). We observed a similar trend with simultaneous CHIR and FGF8b treatment inducing uniform Brachyury but also causing a sharp decrease in SOX2 expression (23% ± 0% SOX2^+^), indicating a mesodermal fate shift ([Figure 2](#fig2){ref-type="fig"}A, Route 1). Conversely, pre-treatment with FGF8b prior to CHIR (pre-FGF8b/CHIR) yielded uniform expression of both Brachyury and SOX2 that could be maintained (75%--100% SOX2^+^/Brachyury^+^) for 7 days ([Figure 2](#fig2){ref-type="fig"}A, Route 2, and [Figure 2](#fig2){ref-type="fig"}B). Thus, FGF signaling upstream of Wnt/β-catenin signaling effectively induces a stable NMP identity during hPSC differentiation.

Next, we investigated whether colinear *HOX* expression was evident within our NMP cultures. Analogous to their in vivo counterparts, these cultures exhibited colinear activation of *HOX* genes over the 7-day period ([Figures 2](#fig2){ref-type="fig"}B--2D; [Figure S2](#app2){ref-type="sec"}). In our system, 3′ *HOX* transcripts remained expressed even after activation of caudal paralogs and fluctuated within an ∼5-fold range ([Figure S2](#app2){ref-type="sec"}A), also agreeing with [@bib16]. Supplementation with GDF11, a transforming growth factor β (TGF-β) family member expressed at later stages of NMP propagation in vivo ([@bib30; @bib31]), was necessary for robust activation of lumbosacral *HOX* paralogs ([@bib42]) ([Figures 2](#fig2){ref-type="fig"}B--2D; [Figure S2](#app2){ref-type="sec"}A) but did not significantly repress transcription of rostral *HOX* genes ([Figure S2](#app2){ref-type="sec"}B) or disrupt the NMP state ([Figure 2](#fig2){ref-type="fig"}B). Moreover, premature GDF11 treatment (initiated after 1 day of FGF8b/CHIR) could induce *HOXD10* but at \>100-fold lower expression compared to GDF11 treatment after 4 days of FGF8b/CHIR, indicating robust lumbosacral patterning requires prior activation of rostral *HOX* genes ([Figure S2](#app2){ref-type="sec"}C). We were able to detect colinear transcription of 33 of the 39 *HOX* genes in hPSC-derived NMP cultures, excluding *HOXB3*, *HOXC12*, and the *HOX13* paralogs, over a time span consistent with posterior neural tube formation according to the Carnegie stages of human development ([Figure S2](#app2){ref-type="sec"}A). Moreover, temporal *HOX* activation was also observed in NMPs derived from IMR90-4 iPSCs ([Figure S2](#app2){ref-type="sec"}D), indicating these mechanisms translate to other hPSC lines. While we believe the lack of *HOXB3* detection was due to experimental or qPCR reagent error, our extensive literature search was unable to find definitive documentation of *HOXC12* or *HOX13* paralog expression in the posterior CNS ([@bib10]).

RA Converts NMPs to Neuroectoderm {#sec2.3}
---------------------------------

In vivo, regression of the stem zone along the primitive streak yields a rostral decline in FGF signaling that coincides with RA secretion from newly formed somites and PAX6 expression in the newly formed neural tube ([@bib14]). This suggests that RA could induce a NMP-to-neuroectoderm fate switch. To test this in vitro, we exposed hPSC-derived NMPs to E6 medium containing RA, CHIR, or neither for 2 days. Cultures exposed to only E6 medium maintained SOX2 and Brachyury expression but gained minimal PAX6 (96% ± 4% SOX2^+^, 15% ± 8% PAX6^+^, 78% ± 16% Brachyury^+^), while exposure to only CHIR induced a mesodermal fate shift as evidenced by SOX2 downregulation, no PAX6 induction, and uniform maintenance of Brachyury expression (50% ± 8% SOX2^+^, 96% ± 1% Brachyury^+^) ([Figure 3](#fig3){ref-type="fig"}A). However, when exposed to RA, the cells gained PAX6 expression along with SOX2 maintenance (98% ± 4% SOX2^+^, 97% ± 3% PAX6^+^) and Brachyury downregulation (43% ± 4%) indicating a neuroectodermal fate shift ([Figure 3](#fig3){ref-type="fig"}A). Moreover, transitioning to RA at any point during NMP propagation generated a highly pure (\>83%) PAX6^+^/SOX2^+^ neuroepithelial culture, i.e., polarized N-cadherin, within 4 days ([Figures 3](#fig3){ref-type="fig"}B--3D). If GDF11 was added to facilitate lumbosacral patterning, PAX6 expression in response to RA was decreased in a dose-dependent manner ([Figures S3](#app2){ref-type="sec"}A--S3C). The ability of GDF11 to control R/C patterning is mediated by signaling via ALK5 ([@bib2]) and activation of the SMAD2/3 complex ([@bib30]). GDF11 has also been shown to activate SMAD1/5/8 in vitro ([@bib30]), which contributes to dorsal patterning ([@bib49]). Since dorsomorphin selectively inhibits ALK2, ALK3, and ALK6, which blocks SMAD1/5/8 signaling ([@bib57]), we hypothesized the addition of dorsomorphin should prevent acquisition of a dorsal phenotype without affecting R/C patterning. Indeed, the addition of dorsomorphin with GDF11 and throughout RA treatment was sufficient to recover PAX6 expression (83% ± 4% PAX6^+^; [Figure S3](#app2){ref-type="sec"}D). Thus, highly pure neuroectoderm cultures could be obtained from NMPs at any point during colinear *HOX* activation.

Deterministic Hox Patterning Can Be Achieved Using a Temporal Transition between Wnt/FGF/GDF and RA Treatment {#sec2.4}
-------------------------------------------------------------------------------------------------------------

Because RA production in vivo and treatment in vitro coincides with neural differentiation, we and others ([@bib13]) posited that it might also serve as a signal to arrest colinear *HOX* activation. We therefore tested the ability of RA to generate neuroectoderm with discrete, region-specific *HOX* expression profiles in accordance with the status of colinear *HOX* activation observed in the NMP state ([Figure 3](#fig3){ref-type="fig"}B). Also, we assessed the expression of HOX transcription factors (TFs) that would demarcate distinct hindbrain and spinal cord domains ([@bib9; @bib10]). First, we evaluated our ability to pattern neuroectoderm to hindbrain domains using a 0- to 30-hr FGF8b/CHIR NMP propagation period prior to 4 days of RA treatment ([Figures 3](#fig3){ref-type="fig"}B and 3C). qPCR analysis of the resulting neuroectoderm cultures revealed elevated expression of H*OXA1* and *HOXA2* prior to *HOXB1*, *HOXB2*, and *HOXB4*. Immunocytochemical analysis revealed that early cultures were HOXB1^+^/HOXB4^−^ (2 hr FGF8b/CHIR, 4 days RA; 63% ± 6% HOXB1^+^) but rapidly lost HOXB1 expression if derived after only an additional 4 hr of NMP propagation (6 hr FGF8b/CHIR, 4 days RA; 5% ± 2% HOXB1^+^) ([Figure 3](#fig3){ref-type="fig"}C). If neuroectoderm was derived after 24 hr of NMP propagation, it reacquired HOXB1 and now also expressed HOXB4 (24 hr FGF8b/CHIR, 4 days RA; 63% ± 5% HOXB1^+^ and 37% ± 8% HOXB4^+^) ([Figure 3](#fig3){ref-type="fig"}C). This mirrors HOX TF expression during development of the fourth, fifth, and sixth through eighth rhombomeres, respectively, indicating that transitioning from Wnt/FGF to RA at the 2- to 4-hr time point generates HOXB1^+^ neuroectoderm that could potentially produce facial nerve MNs whereas transitioning at 24 hr generates HOXB4^+^ neuroectoderm of the caudal hindbrain ([@bib4; @bib42; @bib3]). Interestingly, the high percentage of HOXB1^+^ cells at the 2 hr mark coincided with low *HOXB1* expression (∼10% of the maximum observed expression at 20 hr) suggesting that while transcript levels are useful for identifying relative *HOX* gene expression, they may not be directly instructive for predicting HOX TF profiles that arise due to cross-repressive interactions ([@bib4; @bib9; @bib10]). Also, the observed abrupt transitions in neuroectoderm HOX TF expression suggest fairly uniform progressive *HOX* activation within the NMPs ([Figure 3](#fig3){ref-type="fig"}C).

Next, we performed a similar Wnt/FGF/GDF-to-RA transition time-course analysis focusing on later time points that would generate neuroectoderm patterned to spinal cord domains ([Figures 3](#fig3){ref-type="fig"}B and 3D). qPCR analysis again demonstrated that RA treatment could halt the induction of 5′ paralogs that would otherwise have become expressed in continuous Wnt/FGF/GDF11 treatment. Using both immunocytochemistry and flow cytometry, we observed uniform HOXB4 expression in neuroectodermal cultures derived from NMPs transitioned to RA after 24--48 hr of propagation, correlating to a rostral cervical spinal cord domain ([Figures 3](#fig3){ref-type="fig"}B and 3D). HOXB4 expression dropped sharply (from 84% ± 10% down to 12% ± 4% HOXB4^+^ cells) when the transition to RA occurred at 72 hr ([Figure 3](#fig3){ref-type="fig"}D), which coincided with the initiation of thoracic *HOXC9* expression, a known repressor of *HOX4* paralog expression ([@bib18]). Furthermore, HOXD10 was only detected in neuroectodermal cultures when RA was added after ∼144 hr of NMP propagation ([Figures 3](#fig3){ref-type="fig"}B and 3D; [Figure S3](#app2){ref-type="sec"}E), while HOXB4 remained repressed. Additional insights into the diversity of HOX expression in neuroectoderm patterned to cervical, thoracic, and lumbar spinal cord domains were obtained using quantitative mass spectrometry ([Figure 3](#fig3){ref-type="fig"}E; [Table S1](#mmc2){ref-type="supplementary-material"}). As expected, HOXC9 was expressed in thoracic neuroectoderm but repressed in the HOXD10^+^ lumbar culture, and many (HOXB1, HOXB4, HOXD4, HOXB5, HOXB8, HOXC9, and HOXA10) but not all (HOXB9) detected HOX factors exhibited expression patterns indicative of similar cross-repressive interactions ([@bib10]) ([Figure 3](#fig3){ref-type="fig"}E). Thus, these results demonstrate region-specific patterning of hPSC-derived neuroectoderm in the spinal cord, and similar to the hindbrain neuroectoderm cultures, repression of HOX proteins occurred even though their *HOX* transcripts remained expressed, possibly indicating cross-repressive interactions at this stage are occurring at the post-transcriptional stage ([@bib55]). Hence, our temporal biphasic approach for differentiating hPSCs to neuroectoderm through a stable NMP intermediate enables deterministic *HOX* patterning to impart diverse and discrete hindbrain and spinal cord regional identities ([Figure 3](#fig3){ref-type="fig"}B).

Neuroectoderm with Region-Specific *HOX* Profiles Generate Regional MN Populations {#sec2.5}
----------------------------------------------------------------------------------

We used MN differentiation to evaluate whether the regional specification imparted by our *HOX* patterning approach yielded characteristic differences in the neuroectoderm progeny. First, we verified that MNs derived from neuroectoderm of discrete hindbrain domains likewise exhibited distinct HOX signatures. Hindbrain neuromesoderm was propagated for 4, 12, and 24 hr before conversion to ventralized neuroectoderm using RA, sonic hedgehog (SHH) and purmorphamine (PM, a sonic hedgehog agonist) exposure and further differentiation to MNs using media containing RA and neurotrophic factors (NTFs). MN differentiation was verified by the presence of cells co-expressing βIII-tubulin/ISL1 and SMI-32 reactive non-phosphorylated neurofilament heavy chain with ISL1 or synapsin ([@bib1; @bib25]) ([Figure 4](#fig4){ref-type="fig"}A). Immunocytochemical analysis of HB9^+^ MNs generated from 4 hr neuromesoderm revealed no co-expression of HOXB1 or HOXB4. However, HB9^+^ MNs generated from 12 hr neuromesoderm predominantly co-expressed HOXB1 but not HOXB4, and those generated from 24 hr neuromesoderm predominantly co-expressed both HOXB1 and HOXB4 ([Figure 4](#fig4){ref-type="fig"}A). Also, within all cultures, many ISL1^+^ cells co-expressed PHOX2B indicative of hindbrain identity ([@bib35; @bib40]). Thus, MNs derived from hindbrain neuroectoderm with discrete Hox gene and protein profiles ([Figure 3](#fig3){ref-type="fig"}C) likewise express distinct HOX profiles, although the precise regional identity of these MNs based on their HOX signatures is currently unclear.

In the developed spinal cord, MNs reside in distinct motor columns: the lateral (LMC) and medial motor columns (MMC) at cervical and lumbar levels, and the preganglionic (PGC), MMC, and hypaxial motor column (HMC) at thoracic levels ([@bib42]). MMC MNs exclusively express LHX3 along with HB9 and ISL1, while LMC MNs express LHX1 and FOXP1 with either HB9 or ISL1 depending on their further subdivision into medial and lateral domains ([@bib46; @bib50]). PGC MNs are FOXP1^+^/ISL1^+^/HB9^−^, while HMC MNs are LHX3^−^/FOXP1^−^ but express both HB9 and ISL1 ([@bib11; @bib54]). Thus, quantitative immunocytochemistry can be used to observe whether cervical, thoracic, and lumbar neuroectoderm could be differentiated into MN precursors populations exhibiting relative FOXP1/HB9 co-expression patterns characteristic of their R/C domain in vivo, i.e., the presence of FOXP1^+^/HB9^+^ cells in cervical and lumbar but not thoracic cultures ([@bib11]).

Regional spinal MN precursors were derived by exposing appropriately patterned NMPs to RA and PM for 7 days prior to an additional week of differentiation in neurotrophic factors ([@bib25]) ([Figure 4](#fig4){ref-type="fig"}B). We observed no significant differences in the numbers of FOXP1^+^/ISL1^+^ MN precursors (37% ± 9%, 27% ± 13%, and 26% ± 8%, respectively, of the total ISL1^+^ population). However, FOXP1^+^/HB9^+^ MN precursors were prevalent in cervical and lumbar cultures (23% ± 6% and 18% ± 4% of the total HB9^+^ population) but scarce in thoracic cultures (8% ± 4%; p \< 0.000001, [Figure 4](#fig4){ref-type="fig"}B). We initially expected that no FOXP1^+^/HB9^+^ MN precursors would be present in the thoracic cultures, but PGC MNs proceed through an HB9^+^ state before its expression is rapidly lost ([@bib54]). Therefore, the small subset of FOXP1^+^/HB9^+^ cells in our thoracic cultures likely represents immature PGC MNs. The significant difference in the propensity of cervical and lumbar versus thoracic neuroectoderm to generate FOXP1^+^/HB9^+^ MN precursors characteristic of the LMC demonstrates proper regional specification as a result of our deterministic *HOX* patterning approach.

Furthermore, we investigated whether accelerated MN differentiation induced by treating ventralized cervical (*HOXC6*^*+*^*/HOXC9*^−^*/HOXD10*^−^), thoracic (*HOXC6*^*+*^*/HOXC9*^*+*^*/HOXD10*^−^), and lumbar (*HOXC6*^*+*^*/HOXC9*^*+*^*/HOXD10*^*+*^) ([Figure 3](#fig3){ref-type="fig"}D) neuroectoderm with the Notch signaling inhibitor DAPT ([@bib35]), which yielded \>92% NeuN^+^ neuronal cultures within 7 days ([Figures 4](#fig4){ref-type="fig"}C and [S4](#app2){ref-type="sec"}A), altered the regional specification imposed at the neuroectoderm stage. Each differentiated culture contained MNs co-expressing βIII-tubulin with ISL1 or HB9 and SMI-32 with ISL1 or synapsin ([Figure 4](#fig4){ref-type="fig"}C). RT-PCR analysis revealed that each culture's regional spinal cord identity patterned at the neuroectodermal state was preserved throughout accelerated neuronal differentiation ([Figure 4](#fig4){ref-type="fig"}C). Also, electrophysiological analysis of these cervical, thoracic, and lumbar cultures after additional weeks of maturation determined that each region-specific culture possessed neurons exhibiting mature action potentials ([Figures S4](#app2){ref-type="sec"}B and S4C). Hence, our approach to deterministic patterning of *HOX* expression should be broadly applicable to deriving functional and region-specific hindbrain and spinal cord tissues from hPSCs.

Discussion {#sec3}
==========

Regulation of *HOX* Expression during Posterior Neural Differentiation of hPSCs {#sec3.1}
-------------------------------------------------------------------------------

Our results provide unique evidence that *HOX* expression during posterior neural differentiation of hPSCs can be precisely regulated by temporal control of two opposing mechanisms. Wnt/β-catenin, FGF, and GDF signaling synergistically control colinear *HOX* activation while maintaining an NMP state, and RA arrests *HOX* activation to yield a fixed R/C position and transitions the cultures to definitive neuroectoderm. This approach should enable the derivation of neuroectoderm from any R/C position spanning the hindbrain to lumbosacral spinal cord in a predictable manner.

Specifically, we have demonstrated the ability to generate neuroectoderm with HOX profiles corresponding to specific rhombomeric segments and cervical, thoracic, and lumbosacral vertebral segments. Our findings are distinct from other PSC neural differentiation approaches that unpredictably pattern cells to primarily caudal hindbrain thru cervical *HOX* profiles ([@bib1; @bib23; @bib25]) or to heterogeneous mixtures of cervical, thoracic, and lumbar tissues ([@bib39; @bib41]). Given the data presented in our manuscript, it is perhaps surprising that RA-only patterning approaches can yield *HOX6-8* expression, but this may be inherent to the choice of differentiation methods. Whereas we utilized a chemically defined monolayer system to screen *HOX* patterning cues, most other studies have used embryoid body (EB) cultures for posterior neural differentiation. EB differentiation has been shown to activate endogenous Wnt signaling ([@bib27]), but cells in outer layers of EBs are exposed to different concentrations of soluble media cues than those on the inside of EBs due to diffusional limitations ([@bib52]). Therefore, we suspect in these EB-based systems that competition between endogenous Wnt (activating *HOX* progression) and exogenously added RA (inducing *HOX* arrest and neural differentiation) could cause heterogeneous R/C patterning, especially when considering relative heterogeneity in EB sizes and shapes. In contrast, exposure to soluble factors in our monolayer differentiation system should be more uniform, possibly enabling our enhanced *HOX* patterning precision.

We also provide evidence that Wnt/β-catenin and FGF signaling alone can induce substantial expression of *CDX* genes, which are core regulators of *HOX* expression in vivo, similar to results from tissue explant and other PSC differentiation studies ([@bib16; @bib35; @bib36; @bib38]). Thus, RA and Wnt/FGF signaling may regulate different epigenetic states, which could potentially explain discrepancies between reports of coarse, saltatory *HOX* activation in vitro by RA alone ([@bib36]) versus the induction of organized, colinear *HOX* activation in vivo by the temporal integration of multiple signaling pathways. Moreover, though previous studies have suggested RA serves as a "rostralizing" factor ([@bib42]), our treatment of thoracic or lumbosacral NMPs with RA did not generate rostralized neuroectoderm ([Figure 3](#fig3){ref-type="fig"}D); as such, we postulate these previous studies were actually observing premature termination of *HOX* progression. From our results, we posit that *HOX* patterning may involve a temporal, biphasic mechanism where Wnt/FGF primarily controls colinear *HOX* activation and RA controls its termination. This is different than the widely cited gradient mechanism that supposes RA controls 3′ *HOX* patterning and Wnt/FGF controls 5′ *HOX* patterning ([@bib42]). Our patterning mechanism resonates with a progress/stem zone model that has been heavily scrutinized for limb development ([@bib48]). However, our in vitro approach does not allow us to draw direct conclusions about the role each of these factors plays in *HOX* regulation in vivo. We are instead hopeful that our patterning approach will enable detailed studies of *HOX* regulation in vitro, which could then be used to conduct more informative studies of *HOX* patterning in vivo. In addition, since much of the "Hoxasome" is still poorly understood ([@bib33]), the scalability of our chemically defined, deterministic *HOX* patterning protocol will be invaluable to elucidating the molecular mechanisms underlying Hox regulation of downstream neural cell fates.

Implications for Regenerative Therapies and Disease Modeling {#sec3.2}
------------------------------------------------------------

Recent studies of cell replacement therapy in the anterior CNS using hPSC-derived progenitors have demonstrated that the implanted cells must possess a regional phenotype that mimics endogenous tissues in order to effectively engraft and correct neural deficits ([@bib22; @bib32]). Since *HOX* expression patterns are crucial determinants of cellular phenotype, organization, and neural circuit integration in the developing hindbrain and spinal cord ([@bib42]), our patterning approach could serve as the basis for generating a spectrum of posterior neural progeny with highly specific regional identities that may aid regenerative therapy efforts. Also, regional MN phenotypes exhibit differential susceptibility to several neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) ([@bib6; @bib19]). Our deterministic *HOX* patterning approach will facilitate elucidation of the molecular basis underlying differential susceptibility of iPSC-derived MNs with the same disease-causing mutations but different regional phenotypes, including previously inaccessible hindbrain phenotypes. The ability to execute such experimental paradigms should significantly enhance the utility of iPSC-derived MN disease models to identify relevant pathways of neurodegenerative disease induction and progression ([@bib8; @bib20]).

Experimental Procedures {#sec4}
=======================

Induction and Propagation of NMPs and Differentiation to Neural Fates {#sec4.1}
---------------------------------------------------------------------

H9 hESCs ([@bib47]) (passage 25--45), H9 ishcat2 hESCs ([@bib28]) (passage 33--43), and IMR90-4 iPSCs ([@bib56]) (passage 31--40) were maintained in E8 medium on Matrigel (BD Biosciences) as previously described ([@bib29]). 2 μg/ml doxycycline (Sigma) was used for β-catenin knockdown in the ishcat2 line. To initiate differentiation, hPSCs were passaged with accutase (Life Technologies) onto vitronectin (VTN-NC)-coated ([@bib7]) plates at a density of 1 × 10^5^ cells/cm^2^ with 10 μM ROCK inhibitor (Y27632; R&D Systems) as previously described ([@bib29]). The following day, cells were changed to E6 medium and then changed to E6 medium containing 200 ng/ml FGF8b 24 hr later (PeproTech). After another day, the cells were washed once with 2 ml PBS, accutased for 2 min, and removed from the surface by gentle pipetting. After collection by centrifugation, cells were gently resuspended in E6 medium containing 200 ng/ml FGF8b and CHIR99021 (CHIR, 3 μM for H9 hESCs and 2 μM for IMR90-4 iPSCs; R&D Systems) and re-seeded on VTN-NC-coated plates at a density of 1.5 × 10^5^ cells/cm^2^. 10 μM Y27632 was included during the re-seeding process, and the medium was not changed again until 48 hr after passaging. If extended NMP propagation was required, this passaging process was repeated on day 3 of CHIR treatment (re-seed density of 1.2 × 10^5^ cells/cm^2^), and 50 ng/ml GDF11 (PeproTech) was added on day 4 of CHIR treatment to initiate lumbosacral patterning. For some experiments, 1 μM dorsomorphin (R&D Systems) was included with GDF11. At any point during CHIR treatment, cells were changed to E6 medium containing 1 μM retinoic acid (RA; Sigma) to elicit neural induction and arrest *HOX* progression. For assessment of FOXP1 expression in MN precursors, NMPs were passaged en bloc by scraping and re-seeded in VTN-NC-coated chamber slides at a 1:200 ratio in E6 medium containing 1 μM RA and 100 nM purmorphamine (PM; Cayman Chemicals) for 7 days, followed by an additional 7-day treatment with 10 ng/ml brain-derived neurotrophic factor (BDNF; PeproTech), 10 ng/ml glial-derived neurotrophic factor (GDNF; PeproTech), and cAMP (1 μM; Sigma). For assessment of HOX identity in MNs, NMPs were neuralized and ventralized with 1 μM RA, 2 μM PM, and 1 μg/ml sonic hedgehog (SHH; R&D Systems) for 2 days and then passaged en bloc or with accutase and re-seeded in VTN-NC-coated chamber slides at 2 × 10^4^ cells/cm^2^ in E6 medium containing RA, 10 μM Y27632, 10 ng/ml BDNF, 10 ng/ml GDNF, and 1 μM cAMP for 7--14 days (Y27632 was removed after the first 3 days). 10 nM RA was used for cultures with hindbrain *HOX* signatures, and 1 μM RA was used for cultures with spinal cord *HOX* signatures. 1 μM DAPT (Cayman Chemicals) was included for cultures with spinal cord identity. For extended neuronal differentiation to conduct electrophysiology studies, NMPs were neuralized and ventralized with 1 μM RA, 2 μM PM, and 1 μg/ml SHH, passaged 1:100 onto Matrigel-coated glass coverslips, and cultured for 7 days in E6 medium containing 1 μM RA, 100 nM PM, 100 ng/ml SHH, and 1 μM DAPT. The cultures were then matured in E6 medium containing 10 ng/ml BDNF, 10 ng/ml GDNF, and 1 μM cAMP for at least 2 months prior to electrophysiology measurements. The cells were supplemented with 1 μg/ml mouse laminin (Invitrogen) once per week to help maintain attachment.
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![Wnt/β-Catenin and FGF Signaling Synergistically Coordinate *HOX* Activation during hPSC Differentiation\
(A) *HOX* paralog expression in the hindbrain and spinal cord color-coded to the region where its expression is first detected (modified from a previous report; [@bib42]).\
(B) Timeline of H9 hESC differentiation corresponding to (C)--(E).\
(C) RT-PCR analysis of cultures at days 2--5.\
(D) qPCR analysis at day 5. ^∗^p \< 0.005; ^∗∗^p \< 0.001.\
(E) OTX2 and SOX2 expression at day 5 after RA or CHIR treatment. Scale bars, 100 μm. Adjacent images are the same field.\
(F) qPCR analysis at day 2 using the H9 ishcat2 line with or without doxycycline treatment. ^∗^p \< 0.02; ^∗∗^p \< 0.005.\
(G) qPCR analysis at day 5 using the H9 ishcat2 line with or without doxycycline treatment. ^∗^p \< 0.02; ^∗∗^p \< 0.0001.\
All qPCR data are presented as mean ± SD calculated from independent biological triplicates. H9 data are normalized to the condition yielding maximum expression and ishcat2 data are normalized to each doxycycline-free condition. Statistical significance was calculated using the Student's unpaired t test.](gr1){#fig1}

![Colinear *HOX* Expression in hPSC-Derived NMPs\
(A) Analysis of the NMP phenotype by flow cytometry and immunocytochemistry. Gray histogram, immunoglobulin G (IgG) control; red histogram, label of interest. Scale bars, 100 μm.\
(B) Optimized NMP propagation scheme. The addition of CHIR is denoted as t = 0 hr in all panels. Purity of NMPs was assessed by flow cytometry in the presence or absence of GDF11 (data are presented as mean ± SD). qPCR analysis of *HOXD10* and *HOXD11* was conducted in the presence or absence of GDF11 (expression normalized to the time point of maximum expression).\
(C) Schematic for *HOX* induction in NMPs. "t" indicates time under Wnt, FGF, and GDF signaling.\
(D) qPCR analysis of colinear *HOX* expression normalized to the time point of maximum expression. GDF11 was included according to (B).\
qPCR data in all panels are presented as mean ± SD calculated from technical duplicates. Full profiles for all analyzed genes can be found in [Figure S2](#app2){ref-type="sec"}A. For all flow cytometry data, a minimum of two biological replicates was used to calculate mean ± SD.](gr2){#fig2}

![RA Induces a Neuroectodermal Fate and Halts Colinear *HOX* Activation\
(A) NMPs exposed to RA or CHIR acquire a neuroectodermal or mesodermal fate as assessed by flow cytometry at day 6 (gray histogram, IgG control; red histogram, antigen of interest).\
(B) Schematic for transition from NMPs to neuroectoderm by RA treatment. "t" indicates time under Wnt, FGF, and GDF signaling prior to RA treatment, which halts *HOX* progression to yield a defined rostrocaudal identity.\
(C and D) Representative hindbrain (C) and spinal cord (D) cultures assessed by qPCR, immunocytochemistry, and flow cytometry. For all plots, flow cytometry data are presented as mean ± SD from biological duplicates, and qPCR data are mean ± SD from technical duplicates normalized to the time point of maximum expression for each gene. For hindbrain cultures, HOXB1 and HOXB4 were quantified by immunocytochemistry relative to DAPI^+^ nuclei (technical triplicates per time point, minimum 10,000 cells counted, and relative HOX expression patterns were qualitatively verified across biological duplicates), while SOX2 and PAX6 were quantified by flow cytometry. For spinal cord cultures, HOXD10 was quantified by immunocytochemistry relative to DAPI^+^ nuclei (technical duplicates, \>2,000 cells counted), while SOX2, PAX6, and HOXB4 were quantified by flow cytometry. Scale bars, 100 μm. For (D), dorsomorphin was included with GDF11 and throughout RA treatment (further details in [Figure S3](#app2){ref-type="sec"}).\
(E) Mass spectrometry comparison of HOX profiles in cervical, thoracic, and lumbar neuroectoderm cultures. Cervical differentiation: 1 day FGF8b, 2 days FGF8b/CHIR, 4 days RA; thoracic differentiation: 1 day FGF8b, 6 days FGF8b/CHIR, 4 days RA; lumbar differentiation: 1 day FGF8b, 4 days FGF8b/CHIR, 2 days FGF8b/CHIR/GDF11, 4 days RA. Biological triplicates (neuroepithelium isolated individually from three separate culture wells) were used to calculate statistical significance between cervical, thoracic, and lumbar samples.\
Data are presented as mean ± SD and statistical significance was calculated using the Student's unpaired t test. ^∗^p \< 0.01; ^∗∗^p \< 0.002; ^∗∗∗^p \< 0.0001.](gr3){#fig3}

![Derivation of Region-Specific MNs\
(A) Neuronal maturation from various hindbrain locales. NMPs were propagated for 4, 12, or 24 hr before conversion to ventralized neuroectoderm and differentiation to neurons. DAPI (blue) is overlaid in most images. Scale bars, 20 μm. Quantified data are presented as mean ± SD (four technical replicates, \>100 HB9^+^ cells counted per sample).\
(B) Evaluation of FOXP1 columnar identity in ISL1^+^ and HB9^+^ MNs. Cervical differentiation (C): 1 day FGF8b, 2 days FGF8b/CHIR; thoracic differentiation (T): 1 day FGF8b, 5 days FGF8b/CHIR; lumbar differentiation (L): 1 day FGF8b, 4 days FGF8b/CHIR, 2 days FGF8b/CHIR/GDF11; prior to en bloc passage and further differentiation as indicated. NTFs, neurotrophic factors (described in [Experimental Procedures](#sec4){ref-type="sec"}). For plotted data, open circles are percentages from individual fields and bars indicate the mean. Statistical significance was calculated using the Student's unpaired t test (three to five fields were counted across three biological replicates for each condition, minimum 2,500 cells counted). n.s., p \> 0.02; ^∗∗^p \< 0.000001. Scale bars, 100 μm.\
(C) Neuronal maturation from cervical, thoracic, and lumbar patterned neuroectoderm corresponding to the NMP state described in (B).\
DAPI is overlaid in all images. Scale bars, 20 μm. RT-PCR (50 cycles) demonstrates maintenance of regional identity.](gr4){#fig4}
